Below is a list of grant and award recipients. You may narrow the list down by using the filters below. The list can be sorted by year, last name, and institution. The institution listed reflects the sponsoring institution at the time of grant or award.
Past Recipients Year First Name Last Name Degree Institution Title Grant Amount ($) Subject Area
2019 Zaid Abdel Rahman MD Mayo Clinic Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort (MCAEC).
2019 Jithma Abeykoon MD Mayo Clinic Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).
2019 Sarah Abou Alaiwi MD Dana–Farber Cancer Institute Association of polybromo-associated baf (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).
2019 Iman Aboudalle MD The University of Texas M.D. Anderson Cancer Center Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.
2019 Nour Abuhadra MD The University of Texas M.D. Anderson Cancer Center Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.
2019 Aleesha Adatia MBBS, MD Aga Khan Hospital Dar Es salaam
2019 Asya Agulnik MD, MPH St. Jude Children's Research Hospital, Inc. Impact of Implementing a Pediatric Early Warning System (PEWS) on Hospital Outcomes in Resource-Limited Pediatric Oncology Centers 50,000.00
2019 Jalal Ahmed MD, PhD Icahn School of Medicine at Mount Sinai Targeting the tumor microenvironment to advance CAR T cell therapy for lung cancer 50,000.00
2019 Mihaela Aldea MD, PhD Gustave Roussy Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.
2019 Mansour Alfayez MD, MS The University of Texas M.D. Anderson Cancer Center Smoking is associated with poor risk ELN 2017, cytogenetics/molecular profile, and confers poor survival outcomes in acute myeloid leukemia.
2019 Omar Alhalabi MD The University of Texas M.D. Anderson Cancer Center Investigation of combination therapy with pemetrexed, A2BR inhibitor, and anti-PD-L1 in MTAP deficient bladder cancer 50,000.00
2019 Elysia Alvarez MD, MPH University of California, Davis Improving Care for Adolescent and Young Adult Oncology Patients in Mexico and Central America 50,000.00
2019 Kartik Anand MBBS Houston Methodist Cancer Center Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.
2019 Avani Athauda MBBS The Royal Marsden Hospital Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).
2019 Florence Atrafi MD, MSc Maastricht University A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.
2019 Dilip Babu MD University of Rochester Associations of uncertainty with psychological status and quality of life (QoL) among 527 older patients with advanced cancer.
2019 Tarah Ballinger MD Indiana University Good vibrations: a novel mechanical intervention to understand and preserve musculoskeletal health in early stage breast cancer 200,000.00
2019 Marco Bandini MD Vita-Salute San Raffaele University Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.
2019 Rajat Bansal MD Columbia University Medical Center Phase II, single arm, open label study to assess the efficacy of GLP-2 agonist ZP1846 in the prevention of melphalan induced diarrhea among bone marrow transplant patients 50,000.00
2019 Kaquanta Barlow MD Morehouse School of Medicine 8,500.00
2019 Dulce Barrios Other SUNY Upstate Medical University 8,500.00
2019 Allison Barz Leahy MD The Children's Hospital of Philadelphia Symptom monitoring using patient-reported outcomes in newly diagnosed pediatric cancer patients 50,000.00
2019 Francesca Battaglin MD University of Southern California Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.
2019 Francesca Battaglin MD University of Southern California Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.
2019 Jacob Berchuck MD Dana-Farber Cancer Institute Disparities in lung cancer outcomes for veterans with comorbid mental disorders.
2019 David Bond MD The Ohio State University Second cancer incidence in CLL patients receiving BTK inhibitors.
2019 Gregory Botta MD, PhD Sanford Burnham Prebys Medical Discovery Institute Massively Parallel single-cell RNAseq of Pancreatic Cancer T-cells to Determine Metabolic Influence of Immunosuppression 50,000.00
2019 Sam Brondfield MD University of California, San Francisco Feasibility of implementing a resident oncology video curriculum.
2019 Henriette Burger MBChB Stellenbosch University and Tygerberg Hospital
2019 Maria Alessandra Calegari MD Oncologia Medica, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).
2019 Jad Chahoud MD The University of Texas M.D. Anderson Cancer Center Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors.
2019 Kamal Chamoun MD University Hospitals Seidman Cancer Center Insurance status and survival of multiple myeloma (MM) patients.
2019 Bhavana Chapman MD The University of Texas M.D. Anderson Cancer Center Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: A large, single-institutional experience.
2019 Fo-Ping Chen PhD Sun Yat-sen University Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epstein–Barr virus DNA and TNM stage: A “Big data” analysis of 9,160 endemic cases.
2019 Leonid Cherkassky MD Memorial Sloan Kettering Cancer Center Combining cancer-targeted T cells with checkpoint blockade recruits endogenous anti-tumor immunity 50,000.00
2019 Kelly Chien MD The University of Texas M.D. Anderson Cancer Center Prevention of Therapy-Related Myeloid Neoplasms Associated with Clonal Hematopoiesis of Indeterminate Potential 50,000.00
2019 Kelly Chien MD, BS The University of Texas M.D. Anderson Cancer Center Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes.
2019 Dai Chihara MD, PhD National Cancer Institute Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.
2019 Andrew Chow MD, PhD Memorial Sloan Kettering Cancer Center Assessment of Tim-4+ Pleural Macrophages as Negative Regulators of Anti-Tumor T Cell Immunity in Lung Cancer 50,000.00
2019 Victor Chow MD University of Washington Acalabrutinib in combination with anti-CD19 Chimeric antigen receptor T-cells (CART) in B-cell lymphoma 50,000.00
2019 Mudit Chowdhary MD Rush University Medical Center Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?
2019 Lauren Colbert MD The University of Texas M.D. Anderson Cancer Center Use of Radiomic Characteristics associated with Decreased T-Cell Response to predict In-Field Failure after Definitive Chemoradiation for Anal Squamous Cell Carcinoma 50,000.00
2019 Julie Collins MD, MPH National Cancer Institute Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.
2019 Vincenza Conteduca MD, PhD Dana-Farber Cancer Institute SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) predicts response to platinum-based chemotherapy (PLT).
2019 Pippa Cosper MD, PhD University of Wisconsin Chromosomal instability as a potential mechanism and marker of radiation sensitivity in head and neck cancer 50,000.00
2019 Colleen Cuthbert PhD University of Calgary Patient level factors associated with chronic opioid use in cancer patients.
2019 Matthew Dallos MD Columbia University Medical Center Maximizing androgen deprivation immunogenicity through PD-1 and IL-8 blockade in castration-sensitive prostate cancer 50,000.00
2019 Manon de Vries-Brilland MSc Integrated Centers of Oncology (ICO) Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.
2019 Antonio Di Meglio MD Institut Gustave Roussy Impact of overweight, obesity and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.
2019 Brunella Di Stefano MD Fondazione Policlinico Universitario A. Gemelli-IRCCS-UOC Oncologia Medica Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).